• Product
• The KPA establishes an emergency TFT
• by Apr 20, 2022 06:05am

• Policy
• Expanding the use of Paxlovid with underlying dz over 12 yrs
• by Lee, Jeong-Hwan Apr 20, 2022 06:05am

• Product
• Non-face-to-face tx companies are appealing for regulations
• by Jung, Heung-Jun Apr 20, 2022 06:05am

• Company
• 1 in 3 don't know the right dose of antipyretic drugs
• by Apr 20, 2022 06:05am

• Company
• Hanmi leads the outpatient prescription market in Q1 2022
• by Chon, Seung-Hyun Apr 19, 2022 05:53am

• Company
• The prolonged slump in IPO of pharmaceutical bio
• by Kim, Jin-Gu Apr 19, 2022 05:52am

• Product
• Immunity products fare better “targeting the long COVID mkt
• by Apr 19, 2022 05:52am

• Policy
• MFDS requested supplementary data of Mifepristone
• by Lee, Hye-Kyung Apr 19, 2022 05:52am

• Opinion
• [Desk] R&D capabilities and Moonshot
• by Chon, Seung-Hyun Apr 19, 2022 05:52am

• Company
• Pharmaceutical industry starts face-to-face marketing
• by Kim, Jin-Gu Apr 18, 2022 05:58am